{
    "Question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
    "Comparison": {
        "Switch to Abatacept versus switch to a 2nd TNF Inhibitor. ": {
            "filename": "PICO 24_Comparison 1.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious risk of bias. Lack of blinding.",
                "b": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events.",
                "c": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment.",
                "d": "Downgraded by two levels due to very serious imprecision. Very small sample size, low number of events.",
                "e": "Downgraded by one level due to serious imprecision. Very small sample size.",
                "f": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size.",
                "g": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size, low number of events."
            }
        },
        "Switch to Rituximab versus switch to a 2nd TNF Inhibitor.": {
            "filename": "PICO 24_Comparison 2.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious risk of bias. Lack of blinding.",
                "b": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, low number of events.",
                "c": "Downgraded by one level due to serious risk of bias. Lack of blinding and lack of allocation concealment.",
                "d": "Downgraded by one level due to serious imprecision. Small sample size.",
                "e": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size.",
                "f": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Very small sample size, low number of events.",
                "g": "Downgraded by two levels due to very serious imprecision. Very small sample size, very low number of events."
            }
        },
        "Switch to IL-6 Receptor Inhibitor versus switch to a 2nd TNF Inhibitor. ": {
            "filename": "PICO 24_Comparison 3.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit.",
                "b": "The study Santos-Faria 2019 found that the RR of low disease activity assessed with Simplified Disease Activity Index ≤ 11 was 0.9 (95%CI 0.68 to 1.17), absolute risk reduction 69 per 1000 (95%CI 222 fewer to 118 more). The RR of low disease activity assessed with Clinical Disease Activity Index ≤ 10 was 0.88 (95%CI 0.68 to 1.15), absolute risk reduction 83 per 1000 (95%CI 222 fewer to 104 more)."
            }
        },
        "Switch to a 2nd TNF Inhibitor versus continue same management. ": {
            "filename": "PICO 24_Comparison 5.json",
            "Explanations": {
                "a": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment.",
                "b": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events.",
                "c": "Switch to IFX.",
                "d": "Continue ETN.",
                "e": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Very small sample size.",
                "f": "Downgraded by two levels due to very serious imprecision. Very small sample size, very low number of events.",
                "g": "Downgraded by one level due to serious risk of bias. Lack of blinding of patients and personnel and lack of allocation concealment. Outcome assessors for radiographic outcomes were blinded.",
                "h": "Downgraded by two levels due to very serious imprecision. Very small sample size."
            }
        },
        "Switch to Rituximab versus switch to IL-6 Receptor Inhibitor.": {
            "filename": "PICO 24_Comparison 6.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding.",
                "b": "Downgraded by one level due to serious imprecision. Low sample size.",
                "c": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low sample size."
            }
        },
        "Add Abatacept versus add TNF Inhibitor.": {
            "filename": "PICO 24_Comparison 7.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit.",
                "b": "The study Santos-Faria 2019 found that the RR of low disease activity assessed with Simplified Disease Activity Index ≤ 11 was 0.72 (95%CI 0.49 to 1.06), absolute risk reduction 194 per 1000 (95%CI 354 fewer to 42 more). The RR of low disease activity assessed with Clinical Disease Activity Index ≤ 10 was 0.72 (95%CI 0.5 to 1.05), absolute risk reduction 194 per 1000 (95%CI 346 fewer to 35 more).",
                "c": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."
            }
        }
    },
    "References": {
        "1": "Brown S, Everett CC, Naraghi. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment (Winchester, England). 2018;22(34):1.",
        "2": "Manders SH, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. BioMed Central. 2015;17.",
        "3": "Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. [Review]. Rheumatology. 2017;56(3):417.",
        "4": "Santos-Faria D. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor (TNFi) in rheumatoid arthritis patients who discontinued a first TNFi. ÓRGÃO OfICIAL dA SOCIEdAdE PORTUGUESA dE REUMATOLOGIA. 2019;44:103-13.",
        "5": "Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases. 2007;66(7):893.",
        "6": "Singh JA WG, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Library. 2016(4).",
        "7": "Elmedany SH. Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis. Clin Rheumatol. 2019;38:2109-17.",
        "8": "Iannazzo S, Benucci M, Favalli EG. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting. Clinical & Experimental Rheumatology. 2018;36(3):479."
    }
}